Preview

Pharmacogenetics and Pharmacogenomics

Advanced search

Полиморфизм гена NAT2 в риске развития туберкулёза с множественной лекарственной устойчивостью при ВИЧ-инфекции

https://doi.org/10.37489/2588-0527-2020-2-12-13

About the Authors

Н. Мальцева
НГИУВ — филиал ФГБОУ ДПО РМАНПО Минздрава России
Russian Federation


И. Викторова
НГИУВ — филиал ФГБОУ ДПО РМАНПО Минздрава России
Russian Federation


О. Казанцева
НГИУВ — филиал ФГБОУ ДПО РМАНПО Минздрава России
Russian Federation


А. Ханин
НГИУВ — филиал ФГБОУ ДПО РМАНПО Минздрава России
Russian Federation


References

1. Conaty SJ, Hayward AC, Story A et al. Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiol. Infect. 2004;132(6):1099-1108. DOI: 10.1017/S0950268804002869.

2. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995;332(5):336-7. DOI: 10.1056/NEJM199502023320518.

3. Van Oosterhout JJ, Dzinjalamala FK, Dimba A et al. Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother. 2015;59(10):6175-80. DOI: 10.1128/AAC.01193-15.

4. Mthiyane T, Millard J, Adamson J et al. N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. Antimicrob Agents Chemother. 2020;64(4):e02376-19. DOI: 10.1128/AAC.02376-19.

5. Federal clinical guidelines for the diagnosis and treatment of tuberculosis in patients with HIV infection, 2015. (In Russ). http://roftb.ru/netcat_files/doks2016/rec2016.pdf


Review

For citations:


 ,  ,  ,   . Pharmacogenetics and Pharmacogenomics. 2020;(2):12-13. (In Russ.) https://doi.org/10.37489/2588-0527-2020-2-12-13

Views: 543


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2588-0527 (Print)
ISSN 2686-8849 (Online)